Recently, the 67th Annual Meeting of ASTRO (the American Society for Radiation Oncology), the world’s largest and most influential academic gathering in radiation oncology, was held in San Francisco, drawing over 10,000 top radiotherapy experts and scholars globally. At the meeting, Baheal Pharma’s (stock code: 301015.SZ) portfolio company — pioneering radiosurgery company ZAP Surgical — debuted its leading brain tumor stereotactic radiotherapy robot, the ZAP-X® Gyroscopic Radiosurgery™ Platform. The company showcased the platform’s latest clinical breakthroughs and clinical data.

At the conference, John R. Adler, MD — founder and CEO of ZAP Surgical and the inventor of CyberKnife® system — shared the original inspiration and technical vision behind ZAP-X, drawing strong interest from attending experts. Concurrently, a peer-reviewed scientific study was released, co-authored by teams from Stanford University, Miami Cancer Research Institute and other instititions. The findings revealed dramatic differences in low-dose radiation spill-over to healthy brain tissue across platforms — in some cases up to a 50-fold variation. During brain tumor treatment, ZAP-X offers markedly better protection for healthy brain tissue than conventional, general-purpose radiotherapy machines. Compared to dedicated intracranial radiosurgery systems, ZAP-X delivers equivalent clinical efficacy while reducing treatment time by around 20%, offering higher-quality care for patients with brain metastases.

Comparison chart of the effects of different radiotherapy equipment on V12 in normal brain tissue and the duration of treatment.

Although stereotactic radiosurgery (SRS) has been used for decades, nearly 80% of patients are still unable to access high-quality treatment due to cost, infrastructure, and technical barriers — especially for benign and malignant brain tumors, such as brain metastases.

The ZAP-X system is specifically engineered to optimize precision intracranial radiotherapy. Featuring a proprietary dual-gantry spherical architecture, it delivers thousands of unique, non-coplanar beams, concentrating high-dose radiation in the target while minimizing exposure to surrounding healthy tissue. With sub-millimeter isocentric accuracy, real-time dose imaging, and a collimator leakage rate as low as 0.002%, ZAP-X sets a new standard for both precision and safety, ushering in a new era for global radiosurgery.

Beyond precision and safety, ZAP-X offers significant advantages in deployment and operation. It replaces traditional cobalt-60 sources with a modern X-ray linear accelerator, eliminating the complex management and potential safety risks associated with radioactive isotopes. Its fully self-shielded design removes the need for expensive, underground concrete bunkers, significantly reducing construction costs and improving accessibility. This innovation is globally recognized for “redefining how hospitals manage complex cranial diseases” — without a shielded vault, the system can be installed in sunlit lobbies, and patients can be accompanied by family during treatment, bringing a new dimension of human-centered care to radiotherapy.

ZAP-X at the European Centre for Radiosurgery in Munich, Germany.

Thanks to its advantages in precision brain radiosurgery, the ZAP-X system has obtained market approval in 24 countries and regions worldwide. It is now deployed in over 70 leading medical institutions globally, with more than 5,000 clinical treatments performed to date. In China, Baheal Medical is driving both the clinical implementation and global manufacturing of ZAP-X. Its upcoming high-end manufacturing base in the Beijing Airport Economic Zone will serve as the global production hub, enabling “Made in China, delivered globally,” while also accelerating the localization of this advanced imported radiotherapy technology.

Currently, Baheal Pharma Group has established a comprehensive, disease-spanning strategy in precision oncology radiotherapy, covering brain, body, and cardiac radiation therapy. Going forward, the company will continue to drive the global deployment of cutting-edge radiotherapy technologies through scientific innovation, industrial collaboration, and localized manufacturing — harnessing technology to optimize medical care.

Conference：

【1】Marianayagam N J, Wang Z, Gutierrez A N, et al. (September 16, 2025) A Comparison of Whole-Brain Dose During Stereotactic Radiosurgery for Multiple Metastases Across Technology Platforms. Cureus 17(9): e92442. doi:10.7759/cureus.92442